2.99 USD
▼-0.07-2.29%
盘后 2.51 0.00%
2026-11-20
市值
$244.52M
市盈率
11.77
EPS
0.25
股息率
—
52 周区间
1.65 – 3.19
成交量
510.69K
Beta
-0.02
目标价
12.00
52W 低 1.6552W 高 3.19
价格走势
公司简介
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell...